Covista Gestion
Gestion contrôle des critères 2/4
Le PDG Covista est Steve Beard, nommé en Sep2021, a un mandat de 4.83 ans. La rémunération annuelle totale est $ 17.24M, composée du salaire de 5.8% et des bonus 94.2%, y compris les actions et options de la société. détient directement 1.06% des actions de la société, d'une valeur de $ 47.22M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 4.3 ans et 7.8 ans.
Informations clés
Steve Beard
Directeur général
US$17.2m
Rémunération totale
| Pourcentage du salaire du PDG | 5.80% |
| Durée du mandat du directeur général | 4.8yrs |
| Propriété du PDG | 1.1% |
| Durée moyenne d'occupation des postes de direction | 4.3yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 7.8yrs |
Mises à jour récentes de la gestion
Recent updates
Mise à jour du récit • Jun 26
CVSA: Student Enrollment Momentum And Campus Expansion Will Support Future Upside
The analyst price target for Covista has increased from $130 to $140, with analysts citing updated assumptions on revenue growth, profit margins, and future P/E as the key reasons for the change. What’s in the News for Covista Covista raised its fiscal 2026 revenue guidance to a range of approximately US$1.93b to US$1.945b, compared with the prior range of US$1.9b to US$1.94b, with guidance implying about 8% to 9% year-over-year growth.Seeking Alpha • Jun 03
Covista: Healthcare Education Growth At A Fair Price
Summary Covista (CVSA) is rated Hold, reflecting strong healthcare education positioning but a valuation that prices in much of its growth story. CVSA's enrollment growth, AI-enabled offerings, and robust cash flow support its strategic pivot, yet it trades near peer medians on key valuation multiples. Regulatory risks tied to Title IV funding and ongoing lawsuits warrant a risk premium, tempering the case for aggressive buying at current levels. Peers like PRDO offer lower multiples and stronger cash conversion, while LOPE commands a premium for a cleaner balance sheet and superior cash generation. Read the full article on Seeking AlphaNouveau récit • Apr 22
Health Care Workforce Shortages Will Pressure Capacity Expansion Yet Support Long Term Potential
Catalysts About Covista Covista is a health care education provider focused on training nurses, physicians, veterinarians and behavioral health professionals at scale. What are the underlying business or industry changes driving this perspective?
Nouveau récit • Apr 08
Health Care Workforce Shortages And Digital Learning Will Support This Bullish Long Term Thesis
Catalysts About Covista Covista provides higher education programs focused on health care and related professional fields. What are the underlying business or industry changes driving this perspective?
Nouveau récit • Mar 24
Health Care Workforce Shortages And Flexible Learning Will Support Stronger Long Term Outcomes
Catalysts About Covista Covista focuses on large scale health care education programs serving nursing, medical, veterinary and allied health students across the United States. What are the underlying business or industry changes driving this perspective?Article d’analyse • Sep 27
With EPS Growth And More, Adtalem Global Education (NYSE:ATGE) Makes An Interesting Case
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Article d’analyse • Aug 07
Adtalem Global Education (NYSE:ATGE) Has A Pretty Healthy Balance Sheet
NYSE:ATGE 1 Year Share Price vs Fair Value Explore Adtalem Global Education's Fair Values from the Community and select...Article d’analyse • Jul 07
An Intrinsic Calculation For Adtalem Global Education Inc. (NYSE:ATGE) Suggests It's 44% Undervalued
Key Insights Adtalem Global Education's estimated fair value is US$221 based on 2 Stage Free Cash Flow to Equity...Article d’analyse • May 13
There's Reason For Concern Over Adtalem Global Education Inc.'s (NYSE:ATGE) Massive 27% Price Jump
Adtalem Global Education Inc. ( NYSE:ATGE ) shareholders have had their patience rewarded with a 27% share price jump...Article d’analyse • May 07
If EPS Growth Is Important To You, Adtalem Global Education (NYSE:ATGE) Presents An Opportunity
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Article d’analyse • Apr 24
Is Adtalem Global Education (NYSE:ATGE) A Risky Investment?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Article d’analyse • Mar 25
Adtalem Global Education Inc. (NYSE:ATGE) Shares Could Be 48% Below Their Intrinsic Value Estimate
Key Insights Adtalem Global Education's estimated fair value is US$198 based on 2 Stage Free Cash Flow to Equity...Article d’analyse • Mar 11
Subdued Growth No Barrier To Adtalem Global Education Inc.'s (NYSE:ATGE) Price
With a median price-to-earnings (or "P/E") ratio of close to 17x in the United States, you could be forgiven for...Article d’analyse • Feb 24
Is There Now An Opportunity In Adtalem Global Education Inc. (NYSE:ATGE)?
Adtalem Global Education Inc. ( NYSE:ATGE ), is not the largest company out there, but it saw a decent share price...Seeking Alpha • Feb 21
Adtalem Global Education: Surging On Registered Nurse Shortage
Summary Adtalem Global Education Inc.'s financial performance has surged with an underlying nationwide shortage of Registered Nurses and in mental health professionals. A shortage is expected to persist — Adtalem still looks to benefit from secular trends in an aging population, while the long-term performance depends on universities' ability to expand capacity. ATGE stock's surge already reflects a good mid-term earnings performance, making long-term growth required for significant returns. I estimate a fair value of $109.5. Read the full article on Seeking AlphaArticle d’analyse • Jan 21
With EPS Growth And More, Adtalem Global Education (NYSE:ATGE) Makes An Interesting Case
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Article d’analyse • Dec 19
These 4 Measures Indicate That Adtalem Global Education (NYSE:ATGE) Is Using Debt Reasonably Well
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Seeking Alpha • Dec 17
Adtalem Global Education Still Offers Competitive PEG Ratio And Substantial Share Buybacks
Summary The company has shown significant financial progress with improving EBIT and profit margins, indicating efficient cost management. Current valuation metrics suggest the company is rather cheaply priced, despite the good run in 2024. The future outlook remains positive, but investors should be aware of potential risks, such as the debt or future competitive threats from robotics. Read the full article on Seeking AlphaArticle d’analyse • Nov 26
Adtalem Global Education Inc.'s (NYSE:ATGE) Shares Climb 27% But Its Business Is Yet to Catch Up
Adtalem Global Education Inc. ( NYSE:ATGE ) shareholders would be excited to see that the share price has had a great...Article d’analyse • Oct 31
Should You Think About Buying Adtalem Global Education Inc. (NYSE:ATGE) Now?
Adtalem Global Education Inc. ( NYSE:ATGE ), is not the largest company out there, but it led the NYSE gainers with a...Article d’analyse • Oct 16
Should You Be Adding Adtalem Global Education (NYSE:ATGE) To Your Watchlist Today?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Seeking Alpha • Oct 04
Adtalem Global Education Faces Problems But Is Growing Steadily
Summary Adtalem Global Education focuses on medical and veterinary education, showing solid profitability and potential growth in a booming healthcare industry. Despite a current ratio below 1.0, ATGE maintains a reasonable price/book ratio and generates significant operating cash flow, indicating financial stability. Risks include reliance on government financial aid, maintaining accreditation, and ensuring student placements in healthcare jobs, which are crucial for sustaining reputation and revenue. With projected revenue growth and a forward P/E ratio of 13.12, Adtalem Global is a cautious buy, offering portfolio diversity in a growing sector. Read the full article on Seeking AlphaArticle d’analyse • Sep 16
Adtalem Global Education (NYSE:ATGE) Seems To Use Debt Quite Sensibly
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Article d’analyse • Aug 29
Adtalem Global Education Inc.'s (NYSE:ATGE) Price In Tune With Earnings
With a price-to-earnings (or "P/E") ratio of 20.7x Adtalem Global Education Inc. ( NYSE:ATGE ) may be sending bearish...Article d’analyse • Aug 14
We Think Adtalem Global Education's (NYSE:ATGE) Robust Earnings Are Conservative
Even though Adtalem Global Education Inc.'s ( NYSE:ATGE ) recent earnings release was robust, the market didn't seem to...Article d’analyse • Jul 28
Should You Think About Buying Adtalem Global Education Inc. (NYSE:ATGE) Now?
While Adtalem Global Education Inc. ( NYSE:ATGE ) might not have the largest market cap around , it led the NYSE...Seeking Alpha • Jul 27
Adtalem Global Education: Still Undervalued After The Latest Rally
Summary Adtalem Global Education is set to report earnings on August 6th. The company specializes in healthcare education, with Chamberlain and Walden Universities under its wing, showing revenue growth post Walden acquisition. Financials show decent margins, but efficiency metrics trending down, with potential for top-line growth and margin expansion in the future. Read the full article on Seeking AlphaArticle d’analyse • Jul 12
Does Adtalem Global Education (NYSE:ATGE) Deserve A Spot On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Article d’analyse • Jun 14
Adtalem Global Education (NYSE:ATGE) Has A Pretty Healthy Balance Sheet
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$250m |
| Dec 31 2025 | n/a | n/a | US$254m |
| Sep 30 2025 | n/a | n/a | US$247m |
| Jun 30 2025 | US$17m | US$1m | US$233m |
| Mar 31 2025 | n/a | n/a | US$229m |
| Dec 31 2024 | n/a | n/a | US$204m |
| Sep 30 2024 | n/a | n/a | US$172m |
| Jun 30 2024 | US$14m | US$987k | US$138m |
| Mar 31 2024 | n/a | n/a | US$111m |
| Dec 31 2023 | n/a | n/a | US$122m |
| Sep 30 2023 | n/a | n/a | US$108m |
| Jun 30 2023 | US$8m | US$950k | US$102m |
| Mar 31 2023 | n/a | n/a | US$79m |
| Dec 31 2022 | n/a | n/a | US$35m |
| Sep 30 2022 | n/a | n/a | US$47m |
| Jun 30 2022 | US$9m | US$828k | -US$36m |
| Mar 31 2022 | n/a | n/a | -US$35m |
| Dec 31 2021 | n/a | n/a | -US$15m |
| Sep 30 2021 | n/a | n/a | -US$26m |
| Jun 30 2021 | US$3m | US$600k | US$63m |
| Mar 31 2021 | n/a | n/a | US$139m |
| Dec 31 2020 | n/a | n/a | US$269m |
| Sep 30 2020 | n/a | n/a | US$246m |
| Jun 30 2020 | US$2m | US$598k | US$220m |
Rémunération vs marché: La rémunération totale de Steve ($USD 17.24M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 6.95M ).
Rémunération et revenus: La rémunération de Steve a augmenté de plus de 20 % au cours de l'année écoulée.
PDG
Steve Beard (55 yo)
4.8yrs
Titularisation
US$17,244,988
Compensation
Mr. Stephen W. Beard, also known as Steve, J.D., serves as an Independent Director at Planet Fitness, Inc. since February 9, 2026. He served as Chief Operating Officer at Adtalem Global Education Inc. sinc...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO & Chairman | 4.8yrs | US$17.24m | 1.06% $ 47.2m | |
| Senior VP & CFO | 5.3yrs | US$2.02m | 0.13% $ 6.0m | |
| Senior VP of Institutional Support Services | 5.1yrs | US$1.65m | 0.096% $ 4.3m | |
| Chief Growth & Innovation Officer and President of Walden University | 4.2yrs | US$2.59m | 0.069% $ 3.1m | |
| President of Adtalem Medical & Veterinary | 2.3yrs | US$1.62m | 0.022% $ 968.4k | |
| VP & Chief Accounting Officer | 4.3yrs | pas de données | 0.0091% $ 405.8k | |
| Vice President of Investor Relations | no data | pas de données | pas de données | |
| Senior VP & Chief Human Resources Officer | 1.8yrs | pas de données | 0.0083% $ 368.0k | |
| Senior VP & Chief Corporate Affairs Officer | 1.2yrs | pas de données | pas de données | |
| President of Chamberlain University | no data | pas de données | pas de données | |
| President of Chamberlain University | 7.9yrs | US$1.14m | 0.083% $ 3.7m | |
| Vice President of Treasury & Risk Management | no data | pas de données | pas de données |
4.3yrs
Durée moyenne de l'emploi
56yo
Âge moyen
Gestion expérimentée: L'équipe de direction de CVSA est considérée comme expérimentée (ancienneté moyenne 4.3 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO & Chairman | 4.8yrs | US$17.24m | 1.06% $ 47.2m | |
| Director Emeritus | no data | US$108.37k | pas de données | |
| Director Emeritus | 12.7yrs | US$95.00k | pas de données | |
| Independent Director | 9.5yrs | US$250.17k | 0.026% $ 1.2m | |
| Lead Independent Director | 10.1yrs | US$251.42k | 0.41% $ 18.1m | |
| Independent Director | 6.3yrs | US$225.17k | 0.054% $ 2.4m | |
| Independent Director | 7.8yrs | US$237.67k | 0.020% $ 886.5k | |
| Director | 17.7yrs | US$273.17k | 0.13% $ 5.6m | |
| Independent Director | 6.3yrs | US$237.67k | 0.040% $ 1.8m | |
| Independent Director | 2.5yrs | US$225.17k | 0.0034% $ 149.2k | |
| Independent Director | 8.2yrs | US$237.67k | 0.047% $ 2.1m | |
| Independent Director | 4.1yrs | US$225.17k | 0.044% $ 1.9m |
7.8yrs
Durée moyenne de l'emploi
67yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de CVSA sont considérés comme expérimentés (ancienneté moyenne 7.8 ans).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/07/12 13:22 |
| Cours de l'action en fin de journée | 2026/07/10 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/06/30 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d'analyse utilisé pour générer ce rapport sont disponibles sur notre page Github, nous proposons également des guides pour apprendre à utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Covista Inc. est couverte par 24 analystes. 4 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Gary Bisbee | Barclays |
| Gary Prestopino | Barrington Research Associates, Inc. |
| Alexander Paris | Barrington Research Associates, Inc. |